Regeneron Pharmaceuticals (REGN) Receivables - Other (2009 - 2020)

Regeneron Pharmaceuticals has reported Receivables - Other for 12 years, with the latest figure at $460.8 million in Q3 2020.

• For the quarter ending Q3 2020, Receivables - Other rose 33.41% year-over-year to $460.8 million; the trailing twelve-month figure through Sep 2020 stood at $460.8 million (up 33.41% YoY), and the FY2019 full-year result was $260.6 million, up 15.11% from the prior year.
• Receivables - Other for Q3 2020 stood at $460.8 million, up from $389.2 million in the prior quarter.
• The five-year high for Receivables - Other was $468.3 million in Q1 2020, with the low at $93.0 million in Q4 2016.
• Average Receivables - Other over 5 years is $249.8 million, with a median of $226.4 million recorded in 2018.
• Year-over-year, Receivables - Other sank 39.28% in 2016 and jumped 108.3% in 2017.
• Tracing REGN's Receivables - Other over 5 years: stood at $93.0 million in 2016, then jumped by 108.3% to $193.7 million in 2017, then grew by 16.88% to $226.4 million in 2018, then climbed by 15.11% to $260.6 million in 2019, then jumped by 76.82% to $460.8 million in 2020.
• The last three Receivables - Other figures came in at $460.8 million (Q3 2020), $389.2 million (Q2 2020), and $468.3 million (Q1 2020), per Business Quant data.

Peer Comparison